Methods for treating myositis using fcrn antagonists
Assigneeargenx BV
InventorsSebastian Paul van der Woning, Olivier Boyer, Laurent Drouot
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating myositis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of myositis and for use in the manufacture of a medicament for the treatment of myositis are also provided herein.
Claims44
A method of treating myositis in a subject in need thereof, the method comprising administering to the subject an effective amount of a human neonatal Fc receptor (FcRn) antagonist, wherein the FcRn antagonist comprises or consists of a variant Fc region or FcRn binding fragment thereof.
2-5. (canceled)
(canceled)
(canceled)
(canceled)
14-16. (canceled)
(canceled)
22-26. (canceled)
28-30. (canceled)
(canceled)
34-39. (canceled)
41-44. (canceled)
46-47. (canceled)
50-52. (canceled)
54-55. (canceled)
57-60. (canceled)
(canceled)
(canceled)
66-70. (canceled)
A method of treating myositis in a subject that has received a first FcRn antagonist and is receiving a corticosteroid dosing regimen, the method comprising:
- a) administering to the subject an effective amount of a second FcRn antagonist;
- b) measuring in vitro a serum level of an MAA or an MSA in a blood sample taken from the subject;
- and
- c) comparing the serum level of the MAA or the MSA to a reference value associated with myositis in the subject,
- wherein the corticosteroid dosing regimen is maintained if the serum level of the MAA or the MSA in the sample is greater than or equal to the reference value, or wherein the corticosteroid dosing regimen is tapered if the serum level of the MAA or the MSA is less than the reference value.
A method for treating myositis in a subject comprising:
- (a) administering to the subject one or more initial doses of an effective amount of a first FcRn antagonist,
- (b) administering to the subject one or more further doses of an effective amount of a second FcRn antagonist if the serum level of an MAA or an MSA in the subject after step (a) is greater than or equal to a reference value associated with myositis in the subject, or discontinuing treatment with the first FcRn antagonist if the serum level of the MAA or the MSA in the subject after step (a) is less than a reference value associated with active disease in the subject.
A method for treating myositis in a subject, the method comprising:
- administering to the subject an effective amount of a second FcRn antagonist,
- wherein the myositis has relapsed in the subject following prior therapy with a first FcRn antagonist and wherein the subject has a serum level of an MAA or an MSA that is greater than or equal to a reference value associated with myositis in the subject.
74-102. (canceled)
Dependencies are inferred from the claim text.